Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 162 publications.

Brufsky A, Davis K, Mitra D, Nagar S, McRoy L, Cotter M, Stearns V. Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2– advanced breast cancer enrolled in an expanded access program in the United States. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 8, 2017. San Antonio, TX.

Haleem MS, Han L, van Hemert J, Li B, Fleming A, Pasquale LR, Song BJ. A novel adaptive deformable model for automated optic disc and cup segmentation to aid glaucoma diagnosis,. J Med Syst. 2017 Dec 7;42(1):20. doi: 10.1007/s10916-017-0859-4

Karve S, Nagar S, Goyal R, Kaye JA, Mato AR. Adverse events, resource use, and economic burden in patients with mantle cell lymphoma in the United States. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3442. doi: 10.1182/blood.V130.Suppl_1.3442.3442

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400

Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711

Patterson BJ, Buck PO, Carrico J, Hicks K, Curran D, van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and post herpetic neuralgia case avoidance in the US for people previously vaccinated against HZ. Poster presented at the American Society Health System Pharmacist (ASHP) Midyear Clinical Meeting and Exhibition; December 5, 2017. Orlando, FL.

Purser M, Mladsi D, Beckman A, Barion F, Forsey J. Expected budget impact of expanded use of VNS Therapy®. Poster presented at the American Epilepsy Society 71st Annual Meeting; December 2, 2017. Washington, DC.

Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6

Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9

Goyal R, Karve S, Nagar S, Kaye JA, Mato AR. Real-world treatment patterns and associated adverse events among patients with mantle cell lymphoma (MCL) in the United States. Blood. 2017 Dec;130(Suppl 1):5650. doi: 10.1182/blood.V130.Suppl_1.5650.5650

Phan NTN, Tran TD, Thai KM, Le MT. 3D-Pharmacophore modeling on allosteric inhibitors of RAC Serin/Threonin Protein Kinase AKT1. Poster presented at the Asean Pharm NET 2017; November 21, 2017. Kuala Lumpur, Malaysia.

Candrilli S, Trantham L. Recent trends in congenital cytomegalovirus-related hospitalization in the United States. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.

Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.

Sura SD, Goyal RK, Adhikari D, Mehta HB. Association of multiple chronic conditions with health-related quality of life and physical functioning. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 7, 2017. Glasgow, Scotland.

Emery P, van Keep M, Beard SM, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.

Chiva-Razavi S, Jain M, Graham CN, Miles L, Nikoglou E, Gunda P. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis: a Canadian perspective. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.

Goyal RK, Sura SD, Mehta HB. Direct medical costs of hypoglycemia hospitalizations in the United States. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.

Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.

Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2017 ISPOR 20th Annual European Congress; November 5, 2017. Glasgow, Scotland. Previously presented at the ISPOR 20th Annual International Meeting.

Earnshaw SR, Mullins CD, Brodtkorb TH. Budget impact analysis I: a 6-step approach. Presented at the 2017 ISPOR 20th Annual European Congress; November 5, 2017. Glasgow, Scotland. Previously presented at the ISPOR 18th Annual European Congress.

Wolowacz S, Briggs A, Lloyd A, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 20th Annual European Congress; November 4, 2017. Glasgow, Scotland. Previously presented at the ISPOR 19th Annual European Congress.

Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017 Nov;2(13):2494-502. doi: 10.1080/21645515.2017.1362515

Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.

Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144

Nadipelli VR, Solem CT, Ronquest NA, Yeh Y, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. Poster presented at the 41st Association of Medical Education and Research in Substance Abuse (AMERSA) Annual National Conference; November 2017. Washington, DC. doi: 10.1080/08897077.2018.1441944

Herring W, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland. Poster presented at the 7th Joint ECTRIMS-ACTRIMS Meeting; October 26, 2017. Paris, France.

Hutchinson AB, Hicks KA, Carrico J, Sansom SL. Cost-effectiveness of screening high-risk heterosexuals for HIV in the United States. Poster presented at the 39th Annual Society for Medical Decision Making Annual North American Meeting; October 24, 2017. Pittsburgh, PA.

Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609

Peloquin F, Breton MC, Wasserman M, Wilson M, McDade C, Farkouh R. Pneumococcal vaccination provides substantial value for money for Canadians. Presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.

Wasserman M, Wilson M, McDade C, Grajales AG, Palacios MG, Baez- Revueltas FB, Farkouh R. Estimating the clinical and economic impact of maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico. Presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.

Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.

Walton SM, Harrigan (Zhang) K, Touchette DR. Vesicular monoamine transporter 2 (VMAT2) inhibitors for tardive dyskinesia: effectiveness and value. 2017.

Parikh R, Kurosky S, Udall M, Chang J, Cappelleri JC, Doherty J, Kaye JA. Treatment patterns and outcomes among platinum-refractory/resistant ovarian cancer patients. Poster presented at the American Association of Cancer Research (AACR) Conference; October 2, 2017. Pittsburgh, PA.

Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189

Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19 guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one year outcomes following percutaneous coronary intervention. Presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct 1; 20(9):A405. doi: 10.1016/j.jval.2017.08.041

Ghantoji SS, Karanth S, El Haddad L, Park AK, Lairson DR, Chemaly RF. Clinical and economic burden of respiratory viral infections in hematopoietic stem cell transplant recipients: the MD Anderson experience. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct; 4(Supple 1):319. doi: 10.1093/ofid/ofx163.748

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.

Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT. Two-stage biomarker protocols for early detection of prostate cancer. Med Decis Making. 2017 Oct;37(7):815-26. doi: 10.1177/0272989X17696996

Kohlmeier M, Dong OM. Nutrigenetics in practice. Presented at the 2017 Congress of the International Society of Nutrigenetics & Nutrigenomics; September 16, 2017. Los Angeles, CA. Previously presented at the 2015 Congress of the International Society of Nutrigenetics & Nutrigenomics.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.

Guerci B, Raccah D, Lew E, Meyers J, Shaunik A, Ajmera M, Davis KL, Blonde L. Clinical benefit of simultaneous initiation of basal insulin and GLP-1 in patients with type 2 diabetes and elevated HbA1c as supported by real-world evidence. Poster presented at the EASD 2017 Annual Meeting; September 14, 2017. Lisbon, Portugal.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Bhatt M, Ghio M, Nangia A, Sadri L, Plauche L, Dechert T. Understanding the broken heart: risk factors and outcomes for Takotsubo's cardiomyopathy in critically injured trauma patients. Poster presented at the 76th Annual Meeting of the American Association for the Surgery of Trauma and Clinical Congress of Acute Care Surgery; September 2017. Baltimore, MD.

Earnshaw SR, Mullins D, Brogan A, Hogue S. Building a budget impact model: budget impact analysis training. Presented at the 2017 ISPOR Training Courses; September 2017. New Brunswick, NJ.

Rausch D, Levin MJ, Meyers JL, Candrilli SD, Yan S, Krishnarajah G, Patterson B. Cost of herpes zoster and related complications in patients with immunocompromising conditions aged ≥50 years: a US insurance claims data analysis. Presented at the AAFP Family Medicine Experience; September 2017. San Antonio, TX.

Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A. Multiple risk factor interventions for primary prevention of CVD in LMIC: a Cochrane review. Glob Heart. 2017 Sep;12(3):199-208.e. doi: 10.1016/j.gheart.2016.03.639

Kelly SA, Hartley L, Loveman E, Colquitt JL, Jones HM, Al-Khudairy L, Clar C, Germano R, Lunn HR, Frost G, Rees K. Whole grain cereals for the primary or secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD005051. doi: 10.1002/14651858.CD005051.pub3

Wolowacz S, Mauskopf J, Earnshaw SR. Determining the analytic framework. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.11-34. doi: 10.1007/978-3-319-50482-7

Wolowacz S, Mauskopf J, Earnshaw SR. Estimating condition-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.91-101. doi: 10.1007/978-3-319-50482-7

Brogan A, Earnshaw SR, Mauskopf J. The computing framework and calculations. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.103-28. doi: 10.1007/978-3-319-50482-7